The T4/T3 quotient as a risk factor for differentiated thyroid cancer: A case control study
Open Access
- 1 January 2017
- journal article
- research article
- Published by SAGE Publications in Journal of Otolaryngology - Head & Neck Surgery
- Vol. 46 (1) , 28
Abstract
Background: The incidence of thyroid nodules is increasing among patients in North America. Few of these nodules harbour malignancy, thus further research is required to identify predictive markers of malignant thyroid disease. This study set out to understand the relationship between the levels of fT4 and fT3 and differentiated thyroid cancer. Methods: A case-control study was conducted with 142 cases and 86 controls from the McGill University Teaching Hospitals. All patients underwent thyroid surgery. Cases were defined as patients with malignant nodules confirmed on final pathology and controls were defined as patients with benign nodules. The serological levels of TSH, fT4 and fT3 were measured preoperatively. Odds ratios were determined for each parameter and logistic regressions were calculated between markers and probability of malignancy. Additionally, fT4 values were divided by fT3 values (fT4/fT3 quotient) for each patient and an odds ratio was calculated. Results: Amongst cases, the mean TSH was 2.25 ± 0.360U/mL, fT4 was 14.8 ± 0.689pmol/L, and fT3 was 4.65 ± 0.463pmol/L. Amongst controls, the mean TSH was 2.36 ± 1.68U/mL, fT4 was 14.3 ± 1.71pmol/L, and fT3 was 5.27 ± 0.957pmol/L. Patients in the control group were more likely to have low TSH, while patients in the case group would have high fT4 and patients in the control group were more likely to have a low fT4. The OR for patients with TSH >4.4U/mL was 2.13 (0.97, 4.65), and for patients with TSH 16pmol/L was 2.10 (1.09, 4.06), and for patients with fT4 < 10pmol/L was 0.45 (0.20, 0.98). The OR for patients with fT3 > 5.5pmol/L was 0.39 (0.14, 1.28). The OR for patients with fT3 < 3pmol/L was 1.83 (0.25, 13.69). The average fT4/fT3 was 3.39 ± 0.206 for cases and 2.93 ± 0.467 for controls. The fT4/fT3 quotient was considered high if it was >3.3 (OR =6.00 (2.94, 12.25)). Conclusion: In this study, a direct relationship between high levels of fT4 and malignancy was uncovered. Furthermore, low levels of TSH and fT4 increased the likelihood that a nodule was benign. In this study a fT4/fT3 ratio >3.3 increased the risk of malignancy by 3.6 times ( p-value =0.0013).Keywords
This publication has 28 references indexed in Scilit:
- The association between serum TSH concentration and thyroid cancerEndocrine-Related Cancer, 2009
- Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extensionClinical Endocrinology, 2009
- Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005Cancer Epidemiology, Biomarkers & Prevention, 2009
- Epidemiology of thyroid nodulesBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Endogenous Thyrotropin and Triiodothyronine Concentrations in Individuals with Thyroid CancerThyroid®, 2008
- Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodulesJournal of Cancer Research and Clinical Oncology, 2008
- Higher Serum Thyroid Stimulating Hormone Level in Thyroid Nodule Patients Is Associated with Greater Risks of Differentiated Thyroid Cancer and Advanced Tumor StageThe Journal of Clinical Endocrinology & Metabolism, 2008
- Disturbed Expression of Type 1 and Type 2 Iodothyronine Deiodinase As Well As Titf1/Nkx2-1 and Pax-8 Transcription Factor Genes in Papillary Thyroid CancerThyroid®, 2005
- Ultrasound of thyroid cancerCancer Imaging, 2005
- Fine Needle Aspiration Biopsy in the Management of Thyroid NodulesThe Endocrinologist, 1991